 Nirmala Parajuli
Concepts (162)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 9 | 2025 | 199 | 4.090 |
Why?
| | Kidney | 13 | 2025 | 716 | 3.450 |
Why?
| | Organ Preservation | 6 | 2025 | 33 | 2.330 |
Why?
| | Proteasome Endopeptidase Complex | 4 | 2024 | 137 | 2.130 |
Why?
| | Cryopreservation | 4 | 2020 | 41 | 1.570 |
Why?
| | Mitochondria | 6 | 2020 | 420 | 1.510 |
Why?
| | Reperfusion Injury | 2 | 2025 | 73 | 1.270 |
Why?
| | Rats | 13 | 2025 | 3228 | 1.190 |
Why?
| | Superoxide Dismutase | 5 | 2014 | 120 | 1.000 |
Why?
| | Complement C5 | 1 | 2025 | 4 | 0.960 |
Why?
| | Interferon-gamma | 4 | 2023 | 169 | 0.880 |
Why?
| | Phosphoproteins | 1 | 2025 | 123 | 0.860 |
Why?
| | Animals | 23 | 2025 | 13485 | 0.860 |
Why?
| | Metformin | 1 | 2025 | 82 | 0.840 |
Why?
| | Proteome | 1 | 2025 | 175 | 0.810 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 223 | 0.800 |
Why?
| | Transplants | 1 | 2023 | 19 | 0.780 |
Why?
| | Cold Temperature | 3 | 2021 | 52 | 0.770 |
Why?
| | Acute Kidney Injury | 2 | 2025 | 389 | 0.750 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 198 | 0.740 |
Why?
| | Complement System Proteins | 1 | 2021 | 32 | 0.700 |
Why?
| | Rats, Inbred Lew | 4 | 2025 | 49 | 0.690 |
Why?
| | Mitochondrial Proteins | 2 | 2019 | 91 | 0.670 |
Why?
| | Cold Ischemia | 1 | 2018 | 11 | 0.590 |
Why?
| | Obesity | 1 | 2025 | 1176 | 0.510 |
Why?
| | Organophosphorus Compounds | 2 | 2014 | 18 | 0.490 |
Why?
| | STAT1 Transcription Factor | 4 | 2023 | 24 | 0.480 |
Why?
| | Kidney Tubules | 2 | 2012 | 63 | 0.460 |
Why?
| | Receptor, erbB-2 | 3 | 2013 | 79 | 0.410 |
Why?
| | Oxidative Stress | 5 | 2025 | 805 | 0.400 |
Why?
| | Mitochondrial Turnover | 1 | 2012 | 4 | 0.390 |
Why?
| | Ubiquinone | 1 | 2012 | 14 | 0.390 |
Why?
| | Cytokines | 2 | 2021 | 622 | 0.390 |
Why?
| | Disease Models, Animal | 4 | 2025 | 1483 | 0.360 |
Why?
| | Autophagy | 1 | 2012 | 185 | 0.340 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2010 | 62 | 0.320 |
Why?
| | Reactive Oxygen Species | 2 | 2024 | 415 | 0.320 |
Why?
| | Male | 9 | 2025 | 26874 | 0.320 |
Why?
| | Inflammation | 2 | 2025 | 649 | 0.310 |
Why?
| | Cytostatic Agents | 1 | 2009 | 2 | 0.310 |
Why?
| | Signal Transduction | 3 | 2025 | 1724 | 0.310 |
Why?
| | Tissue Culture Techniques | 1 | 2009 | 42 | 0.310 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2009 | 33 | 0.300 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2010 | 122 | 0.300 |
Why?
| | Cell Line | 3 | 2021 | 1020 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2025 | 390 | 0.270 |
Why?
| | Gene Knockout Techniques | 2 | 2025 | 50 | 0.260 |
Why?
| | Time Factors | 3 | 2025 | 2987 | 0.260 |
Why?
| | Doxorubicin | 3 | 2013 | 246 | 0.250 |
Why?
| | Mice, Transgenic | 4 | 2013 | 566 | 0.240 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 65 | 0.230 |
Why?
| | Rats, Zucker | 1 | 2025 | 73 | 0.230 |
Why?
| | Mice | 9 | 2014 | 5899 | 0.220 |
Why?
| | Apoptosis | 2 | 2025 | 1120 | 0.220 |
Why?
| | Peroxynitrous Acid | 1 | 2024 | 33 | 0.210 |
Why?
| | Administration, Oral | 1 | 2025 | 455 | 0.210 |
Why?
| | Cell Death | 3 | 2020 | 169 | 0.210 |
Why?
| | Proteasome Inhibitors | 1 | 2024 | 101 | 0.200 |
Why?
| | STAT3 Transcription Factor | 1 | 2023 | 89 | 0.190 |
Why?
| | Proteomics | 1 | 2025 | 332 | 0.190 |
Why?
| | Rats, Sprague-Dawley | 1 | 2025 | 1558 | 0.180 |
Why?
| | Phosphorylation | 1 | 2023 | 536 | 0.180 |
Why?
| | Complement Activation | 1 | 2021 | 27 | 0.170 |
Why?
| | Kidney Tubules, Proximal | 1 | 2021 | 60 | 0.170 |
Why?
| | Rats, Inbred F344 | 1 | 2021 | 194 | 0.170 |
Why?
| | Thiourea | 1 | 2020 | 8 | 0.170 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 1 | 2020 | 12 | 0.160 |
Why?
| | Tetrazoles | 1 | 2020 | 41 | 0.160 |
Why?
| | Fluorometry | 1 | 2019 | 2 | 0.150 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 2 | 2009 | 9 | 0.150 |
Why?
| | Metalloendopeptidases | 1 | 2019 | 70 | 0.150 |
Why?
| | Nephrectomy | 1 | 2018 | 81 | 0.140 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 1004 | 0.130 |
Why?
| | Blotting, Western | 1 | 2017 | 587 | 0.120 |
Why?
| | Mice, Knockout | 3 | 2013 | 903 | 0.120 |
Why?
| | B-Lymphocytes | 2 | 2013 | 178 | 0.110 |
Why?
| | Electron Transport Chain Complex Proteins | 1 | 2014 | 10 | 0.110 |
Why?
| | Humans | 6 | 2023 | 52441 | 0.110 |
Why?
| | Quinazolines | 1 | 2013 | 32 | 0.100 |
Why?
| | Piperidines | 1 | 2014 | 99 | 0.100 |
Why?
| | Female | 4 | 2025 | 28277 | 0.100 |
Why?
| | Nephrons | 1 | 2012 | 6 | 0.100 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 83 | 0.100 |
Why?
| | Nitrosation | 1 | 2012 | 3 | 0.100 |
Why?
| | Electron Transport | 1 | 2012 | 24 | 0.100 |
Why?
| | Sus scrofa | 1 | 2012 | 39 | 0.100 |
Why?
| | In Situ Nick-End Labeling | 1 | 2012 | 54 | 0.100 |
Why?
| | Tyrosine | 1 | 2012 | 97 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 140 | 0.090 |
Why?
| | Antioxidants | 1 | 2014 | 255 | 0.090 |
Why?
| | Models, Animal | 1 | 2012 | 230 | 0.090 |
Why?
| | DNA Repair | 1 | 2012 | 194 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 231 | 0.090 |
Why?
| | DNA Primers | 1 | 2011 | 204 | 0.090 |
Why?
| | Sepsis | 1 | 2014 | 236 | 0.080 |
Why?
| | Creatinine | 1 | 2011 | 156 | 0.080 |
Why?
| | TATA-Box Binding Protein | 1 | 2010 | 7 | 0.080 |
Why?
| | RNA, Neoplasm | 1 | 2010 | 45 | 0.080 |
Why?
| | Base Sequence | 1 | 2011 | 632 | 0.080 |
Why?
| | Gene Amplification | 1 | 2010 | 59 | 0.080 |
Why?
| | Proteins | 1 | 2012 | 353 | 0.080 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2009 | 2 | 0.080 |
Why?
| | Treatment Outcome | 1 | 2020 | 5508 | 0.080 |
Why?
| | Interferon Regulatory Factor-1 | 1 | 2009 | 14 | 0.080 |
Why?
| | Chemokine CCL19 | 1 | 2009 | 1 | 0.080 |
Why?
| | Chemokine CCL21 | 1 | 2009 | 4 | 0.080 |
Why?
| | Receptors, CCR7 | 1 | 2009 | 5 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2012 | 1013 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 1429 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 580 | 0.070 |
Why?
| | Vaccines | 1 | 2009 | 47 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 441 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2009 | 132 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 977 | 0.070 |
Why?
| | Blood Glucose | 1 | 2011 | 483 | 0.070 |
Why?
| | Receptors, Glucocorticoid | 1 | 2008 | 35 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2009 | 217 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2014 | 1888 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2010 | 403 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1203 | 0.050 |
Why?
| | Cell Respiration | 2 | 2014 | 42 | 0.050 |
Why?
| | Electron Transport Complex III | 1 | 2014 | 6 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2014 | 7 | 0.030 |
Why?
| | Interleukin-7 | 1 | 2013 | 4 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2014 | 24 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2014 | 22 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2013 | 8 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2014 | 29 | 0.030 |
Why?
| | Renal Circulation | 1 | 2014 | 56 | 0.030 |
Why?
| | Microcirculation | 1 | 2014 | 64 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2013 | 69 | 0.030 |
Why?
| | Chemotaxis | 1 | 2013 | 21 | 0.030 |
Why?
| | Cell Lineage | 1 | 2013 | 92 | 0.030 |
Why?
| | Integrases | 1 | 2013 | 43 | 0.030 |
Why?
| | Genetic Engineering | 1 | 2013 | 24 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 116 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 161 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2014 | 234 | 0.020 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 145 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 271 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 344 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 667 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 618 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2010 | 43 | 0.020 |
Why?
| | Oxidants | 1 | 2010 | 51 | 0.020 |
Why?
| | Transgenes | 1 | 2010 | 55 | 0.020 |
Why?
| | Superoxides | 1 | 2010 | 46 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 1583 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 15 | 0.020 |
Why?
| | Ovalbumin | 1 | 2009 | 19 | 0.020 |
Why?
| | Administration, Sublingual | 1 | 2009 | 17 | 0.020 |
Why?
| | Pharmacokinetics | 1 | 2009 | 14 | 0.020 |
Why?
| | Mouth Mucosa | 1 | 2009 | 27 | 0.020 |
Why?
| | src Homology Domains | 1 | 2008 | 7 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 598 | 0.020 |
Why?
| | COS Cells | 1 | 2008 | 76 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2008 | 52 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2008 | 189 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2009 | 253 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2009 | 318 | 0.020 |
Why?
| | Protein Binding | 1 | 2008 | 673 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2008 | 234 | 0.020 |
Why?
|
|
Parajuli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|